Caffeine analgesic adjuvancy with acetaminophen absent in Bristol-Myers data -- McNeil.
This article was originally published in The Tan Sheet
CAFFEINE ANALGESIC ADJUVANCY NOT SHOWN BY BRISTOL-MYERS SUBMISSION, McNEIL maintains in a recent filing with FDA. The J&J unit is continuing to challenge Bristol-Myers Squibb's attempts to prove that caffeine is effective as an analgesic adjuvant with acetaminophen. Specifically, McNeil maintained that there are "serious carryover effects present in the Bristol-Myers Squibb data and their headache studies do not demonstrate caffeine's adjuvancy when combined with acetaminophen."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC